Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRS-207
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PRS-207 is an investigational oral gut microbiota capsule developed by The First Affiliated Hospital of Nanjing Medical University for the treatment of ulcerative colitis. The therapy consists of a standardized preparation of intestinal microorganisms designed to modulate the gut microbiome and metabolome to induce clinical remission. It is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 0 clinical trial in China, where it is administered as an adjunctive treatment to standard therapy in adult patients with mild to moderate ulcerative colitis. The study aims to characterize the safety profile, clinical efficacy, and the specific changes in microbial diversity and metabolic byproducts associated with the treatment.
- Other names
- PRS-207 gut microbiota capsulePRS207 gut microbiota capsulePRS 207 gut microbiota capsule
Beyond the preview
Go deeper on PRS-207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRS-207.